Lonza to expand inhalation services by adding capabilities at its Tampa (US) site as part of its continued focus on providing bioavailability enhancement series for global customers
The new framework collaboration will support due diligence into ALSA’s potential investments, which will assist with their investment de-risking
Upon closing, the Quakertown business will become an independent company called Microsize
The respective expertise of Lonza and Integral Molecular will benefit drug developers in the assessment of the risk for off-target binding and activation
Under the manufacturing agreement, Lonza will provide drug substance for Asher Bio's cis-targeted IL-2 fusion protein
MilliporeSigma to become the first company to offer a fully integrated ecosystem for advanced process technologies
Through this consortium, Lonza will collaborate with other industry leaders to advance the research and development of inhalation technologies
Christian brings a unique level of experience and expertise from a 20-year career at BASF across multiple territories and businesses
Under the agreement, Lonza will deliver cGMP-standard drug substance for clinical supply
The expansion is part of Lonza’s continued investment in its global manufacturing network, aiming to build a comprehensive offering for global customers
Subscribe To Our Newsletter & Stay Updated
